Organization
Chinese People’s Liberation Army General Hospital
7 abstracts
Abstract
Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma.Org: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Fudan University Shanghai Cancer Center, The Affliated Cancer Hospital of Zhengzhou University,
Abstract
Personalized tumor-informed circulating tumor DNA analysis in monitoring recurrence following resection of high-risk stage II-III gastrointestinal stromal tumor.Org: Peking University People's Hospital, Peking University People’s Hospital, Beijing, China, Burning Rock Biotech, Guangzhou, China, Chinese People’s Liberation Army General Hospital, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China,
Abstract
Genomic and biomarker analysis of immunotherapy combined with chemotherapy treated for patients with metastatic BTC cancer: A real world study.Org: Chinese People's Liberation Army General Hospital, Chinese People’s Liberation Army General Hospital, Senior Department of Oncology, The 5th Medical Center of the PLA General Hospital,
Abstract
Clinical efficacy of avapritinib in gastrointestinal stromal tumors (GIST) with different KIT genotypes: Post hoc analysis of the phase 1 NAVIGATOR and phase 1/2 CS3007-101 trials.Org: Portland VA Health Care System, OHSU Knight Cancer Institute, Portland, OR, Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, The First Affiliated Hospital of Sun Yat-sen University,
Abstract
Antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor (TKI)–resistant succinate dehydrogenase (SDH)–deficient gastrointestinal stromal tumor (GIST).Org: Fudan University Shanghai Cancer Center, Henan Cancer Hospital, Union Hospital Medical College Huazhong University of Science and Technology, Guangdong Provincial People's Hospital, Chinese People’s Liberation Army General Hospital,
Abstract
Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors (GIST) as ≥4th line therapy: Long-term update from a single-arm, phase 2 trial.Org: Peking University Cancer Hospital & Institute, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Fujian Medical University Union Hospital, The First Affiliated Hospital of Chongqing Medical University, Fudan University Shanghai Cancer Center,
Abstract
Comprehensive genomic and transcriptomic profiling analysis of the recurrent gastrointestinal stromal tumor (GIST).Org: ChosenMed Technology (Zhejiang) Co., Ltd., Chinese People’s Liberation Army General Hospital, Beijing Tongren Hospital, Siping Central People’s Hospital,